Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 31;13(2):395.
doi: 10.3390/life13020395.

Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Sara Cherri  1 , Laura Melocchi  2 , Laura Gandolfi  2 , Giulio Rossi  2 , Alberto Zaniboni  1
Affiliations
Review

Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

Sara Cherri et al. Life (Basel). .

Abstract

In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as "untargetable"; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.

Keywords: KRAS; cancer; chemotherapy; colon cancer; multidisciplinary team; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
RAS signaling pathways and main potential targeting therapeutic strategies in colorectal cancer.
See this image and copyright information in PMC

References

    1. Sawicki T., Ruszkowska M., Danielewicz A., Niedźwiedzka E., Arłukowicz T., Przybyłowicz K.E. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers. 2021;13:2025. doi: 10.3390/cancers13092025. - DOI - PMC - PubMed
    1. O’Brien M.J., Gibbons D. The Adenoma-carcinoma Sequence in Colorectal Neoplasia. Surg. Oncol. Clin. N. Am. 1996;5:513–530. doi: 10.1016/S1055-3207(18)30361-2. - DOI - PubMed
    1. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., Jia M., Shepherd R., Leung K., Menzies A., et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2010;39:D945–D950. doi: 10.1093/nar/gkq929. - DOI - PMC - PubMed
    1. Quinlan M.P., Settleman J. Isoform-specific ras functions in development and cancer. Futur. Oncol. 2009;5:105–116. doi: 10.2217/14796694.5.1.105. - DOI - PubMed
    1. Prior I.A., Lewis P.D., Mattos C. A Comprehensive Survey of Ras Mutations in Cancer. Cancer Res. 2012;72:2457–2467. doi: 10.1158/0008-5472.CAN-11-2612. - DOI - PMC - PubMed